Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 3633, June 1, 2008. doi: 10.1158/1078-0432.CCR-07-5155
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, M.
Right arrow Articles by Zhang, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, M.
Right arrow Articles by Zhang, Z.

Cancer Prevention and Susceptibility

A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population

Meilin Wang1,2, Zhizhong Zhang2, Haixia Zhu2, Guangbo Fu3, Shouyu Wang2, Dongmei Wu2, Jianwei Zhou2, Qingyi Wei4 and Zhengdong Zhang1,2

Authors' Affiliations: 1 Key Laboratory of Reproductive Medicine of Jiangsu Province, Nanjing Medical University; and 2 Cancer Center, Nanjing Medical University, Nanjing, China; 3 Department of Urology, The Huai-An First Affiliated Hospital, Nanjing Medical University, Huai-An, China; and 4 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Requests for reprints: Zhengdong Zhang, Department of Molecular Genetic Toxicology, School of Public Health, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China. Phone: 86-25-86862937; Fax: 86-25-86527613; E-mail: zdzhang{at}njmu.edu.cn.

Purpose: MDM2 is believed to regulate the p53 level in modulating DNA repair, cell cycle control, cell growth, and apoptosis. We hypothesize that genetic variants in the MDM2 gene are associated with risk of bladder cancer.

Experimental Design: We first conducted a case-control study of 234 bladder cancer cases and 253 cancer-free controls, using the haplotype-based tagging single nucleotide polymorphism (SNP) approach involving 13 common SNPs initially identified in 100 control subjects. We then examined the functionality of the important SNP.

Results: We found that the C1797G polymorphism in the MDM2 promoter region is an important SNP because its homozygous variant genotype, but none of the haplotypes, was associated with risk of bladder cancer. Electrophoretic mobility shift assay indicated that the 1797C to 1797G transition within the CAAT/enhancer binding protein {alpha} (C/EBP {alpha}) core sequence greatly enhanced the C/EBP{alpha} binding affinity to the promoter region. The in vitro luciferase assays in various cell lines further showed an increased transcriptional activity of the 1797G allele compared with the 1797C allele. Additional experiments with tumor tissues revealed that the transcriptional activator C/EBP{alpha} containing the 1797G allele increased levels of the MDM2 mRNA and protein in bladder tumor tissues.

Conclusions: These data suggested that the novel MDM2 promoter C1797G polymorphism may affect the MDM2 activity by altering the C/EBP{alpha} binding affinity to the promoter and, thus, may be a marker for genetic susceptibility to bladder cancer in Chinese populations. Further validation of the functionality of the MDM2 C1797G polymorphism and its association with risk of bladder and other cancers in other ethnic populations is warranted.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
M. Wang, M. Wang, W. Zhang, L. Yuan, G. Fu, Q. Wei, and Z. Zhang
Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population
Carcinogenesis, June 1, 2009; 30(6): 991 - 996.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
C.-H. CHANG, C.-F. CHIU, S.-Y. LIANG, H.-C. WU, C.-L. CHANG, C.-W. TSAI, H.-C. WANG, H.-Z. LEE, and D.-T. BAU
Significant Association of Ku80 Single Nucleotide Polymorphisms with Bladder Cancer Susceptibility in Taiwan
Anticancer Res, April 1, 2009; 29(4): 1275 - 1279.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Wang, Z. Zhang, Y. Tian, J. Shao, and Z. Zhang
A Six-Nucleotide Insertion-Deletion Polymorphism in the CASP8 Promoter Associated with Risk and Progression of Bladder Cancer
Clin. Cancer Res., April 1, 2009; 15(7): 2567 - 2572.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Z. Zhang, S. Wang, M. Wang, N. Tong, G. Fu, and Z. Zhang
Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis
Carcinogenesis, October 1, 2008; 29(10): 1973 - 1978.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.